CD200 and plasma cell myeloma: Given that blockade of CD200 was recently used in a clinical trial for Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) (Mahadevan et al., 2019), and has been proposed for the treatment of patients with solid tumors such as melanoma, it is necessary to evaluate its potential impacts in more human relevant tumor models.